Older people and people with Alzheimer's disease (AD) show increased sensitivity to antipsychotics, including atypical antipsychotics such as amisulpride. Studies suggest that alterations at the blood-brain barrier (BBB) might cause the increased sensitivity to amisulpride due to increased uptake of the drug in the brain for a given blood drug concentration. In this thesis we aim to examine which transporters are involved in amisulpride transport at the BBB, to verify whether the 5xFamilial Alzheimer's Disease (5xFAD) mouse model is suitable for studying the increased permeability of amisulpride in the brain seen in AD patients, compared to healthy controls, and to understand how the BBB changes in AD compared to healthy ageing. We hypothesise that amisulpride, which is predominantly positively charged at physiological pH, interacts with solute carrier (SLC) transporters at the BBB, and that alterations in the function and/or expression of these BBB transporters are responsible for the increased permeation of amisulpride into the brain in AD compared to healthy ageing. To test this hypothesis we used a combination of literature review, in silico simulations, in vitro studies, mouse model of AD (5xFAD), and studies in human brain tissue from AD and control cases. The increased permeation of atypical antipsychotics like amisulpride into the brain might contribute to the hypersensitivity associated with antipsychotic medication prescribed in Alzheimer's disease. We performed a literature review and analysis of the molecular weight and charge of the established substrates and inhibitors of SLC transporters transporting organic cations and molecules involved in glucose metabolism. These transporters were plasma membrane monoamine transporter (PMAT), multidrug and toxin extrusion transporter 1, 2 (MATE1, 2), organic cation transporter 1 (OCT1), organic cation transporter novel 1, 2 (OCTN1, 2), glucose transporter 1 (GLUT1), monocarboxylate transporter 1 (MCT1). Also, we reviewed the ATP binding cassette (ABC) transporter: P-glycoprotein (P-gp). Next, we used in silico molecular docking to study the interactions between amisulpride and the transporters of interest. In vitro we aimed to confirm the interaction or lack of interaction of the transporters studied in silico with amisulpride in the human cerebral microvessel endothelial cells/D3 (hCMEC/D3). We incubated the cells with [ 3H]amisulpride (3.8-7.7 nM) and [14C]sucrose (0.7-1.5 µM) with or without transporter inhibitors. Also, in a pilot experiment, we studied the effect of amisulpride, and the effect of another antipsychotic – risperidone, on the uptake of [14C]D-glucose into the hCMEC/D3 cells in order to understand the interaction between the antipsychotics and GLUT1. In vivo, we investigated the ultrastructure of the brain capillaries in wild type (WT) and 5xFAD mice using transmission electron microscopy (TEM). We also studied the BBB transport of amisulpride in WT and 5xFAD mice (12-15 months old) via in situ brain perfusions with [3H]amisulpride (6.5 nM) and [14C]sucrose (vascular space marker)(9.4 µM). Western blot (WB) was used to study SLC and ABC transporter expression in isolated mouse brain capillaries. We investigated the ultrastructure of the brain capillaries of an AD case with TEM, as well as the expression of PMAT, GLUT1, MCT1, and P-gp in human control and AD brain capillary samples from the frontal cortex and the caudate, using WB. We compared levels of expression between the control and AD patients, and between the frontal cortex and the caudate. Our molecular docking simulation data suggested that amisulpride interacts with PMAT, MATE1, OCT1, and GLUT1 and MCT1, but not with MATE2, OCT2, OCT3, OCTN1, OCTN2, and P-gp. The interaction of amisulpride with PMAT, MATE1, OCT1, and to an extent GLUT1 is in accord with the typical profile of molecules these transporters interact with, according to our literature review. In hCMEC/D3 cells, PMAT inhibition led to a significant increase in [3H]amisulpride cell accumulation (F (1, 4) = 12.30; p=0.0247; Holm-Sidak multiple comparisons post hoc test; p=0.0332 at 30 minutes, p=0.0116 at 60 minutes, and p=0.0116 at 120 minutes). No effect of amisulpride or risperidone on the accumulation of [14C]D-glucose in the cells was observed. The TEM studies revealed that WT mice and 5xFAD mice at 4.5-6, and 12 months of age had intact brain capillaries. Compared to WT (n=6), the 5xFAD (n=4) mice had increased [ 3H]amisulpride uptake in the brain supernatant (containing the brain parenchyma and interstitial fluid) by 104.86% (t=2.550, df=8, p=0.0342, two-tailed unpaired Student's ttest) but not significantly increased [14C]sucrose passive permeability. WB studies confirmed PMAT, MATE1, GLUT1, MCT1, and P-gp expression in WT and 5xFAD brain capillaries. From our TEM and WB studies in human samples, we can confirm ultrastructural signs of neurodegeneration in an AD case, as well as expression of PMAT, GLUT1, MCT1, and Pgp in control and AD cases. A significant decrease in P-gp expression was observed in the caudate of AD patients compared to controls (t=2.841, df=16, p=0.0118, two-tailed unpaired Student's t-test). Overall, we conclude that SLC transporters (PMAT, MATE1, OCT1, GLUT1, and MCT1) could be implicated in the transport of amisulpride at the BBB. We confirm that the 5xFAD mouse model shows increased brain supernatant permeability to [ 3H]amisulpride compared to WT mice but no significant change in [14C]sucrose permeability. This suggests altered BBB transporter function. In the future, increased number of mice in the perfusion study could allow us to detect specific regional changes in brain permeability. Changes in transporter expression in the mice were not observed which could be because we studied brain capillaries from the whole brain, and regional transporter expression changes can be present in the model. In our human tissue studies we confirm changes in BBB transporter expression with AD. Our evidence for interaction between amisulpride and SLC transporters, as well as present and past evidence for transporter expression changes at the BBB in AD, give further support to the hypothesis that alterations in the function and/or expression of BBB transporters are responsible for the increased permeation of amisulpride into the AD brain, which could be related to the increased sensitivity of AD patients to amisulpride compared to healthy ageing individuals.